Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Indian J Physiol Pharmacol ; 2001 Jan; 45(1): 22-36
Artigo em Inglês | IMSEAR | ID: sea-107141

RESUMO

Insulin resistance has emerged out as a concept linking diabetes mellitus and hypertension. Clinically it is characterized by hyperinsulinemia, hypertension, central obesity, abnormal lipid profile and cardiovascular complications. Insulin resistance is often associated with presence of anti-insulin antibodies and absent or dysfunctional insulin receptors. At molecular level insulin resistance appears to occur at the level of G-protein, kinase activation, glucose carriers (GLUT) and gene expression. Although with advent or research, the molecular mechanisms of insulin resistance are becoming more clear and there is development of new therapeutic agents like insulin sensitizers (thizolidinediones), in clinical practice, as of today, a patient with insulin resistance is looked upon as hypertensive or having diabetes mellitus. Accordingly he is taking either antihypertensives or antidiabetic drugs or both. It is thus essential to look into effects of these agents on insulin sensitivity. In recent years some scattered studies have been conducted to evaluate the effect of various antihypertensives and antidiabetics on insulin sensitivity. An antihypertensive or antidiabetic drug should directly benefit the cardiovascular risk profile of these patients. Although various newer approaches are explored to have a therapeutic benefit in insulin resistance, it is still a long way in the research, when a suitable pharmacological agent with least untoward effects will be available for the treatment of insulin residence.


Assuntos
Fosfatidilinositol 3-Quinase/metabolismo , Animais , Inibidores Enzimáticos/uso terapêutico , Proteínas de Ligação ao GTP/metabolismo , Insuficiência Cardíaca/etiologia , Humanos , Hiperglicemia/complicações , Hipertensão/etiologia , Hipoglicemiantes/uso terapêutico , Resistência à Insulina/fisiologia , Proteínas de Transporte de Monossacarídeos/metabolismo , Fosfotransferases/metabolismo , Transdução de Sinais/fisiologia
2.
Indian J Physiol Pharmacol ; 1999 Apr; 43(2): 160-4
Artigo em Inglês | IMSEAR | ID: sea-107047

RESUMO

Erectile dysfunction is a common and multi-factorial disease that strongly impairs the quality of life in men. During the past decade, many new therapeutic strategies have become available. But the need for oral treatment was strongly felt. This need appears to have been fulfilled with the introduction of sildenafil. The drug acts by enhancing smooth muscle relaxant effect of nitric oxide. A number of clinical studies have now proved its safety and efficacy. The drug has shaken social life all over the world and to accept this "magic pill" or not remains the question of individual choice.


Assuntos
Ensaios Clínicos como Assunto , Interações Medicamentosas , Disfunção Erétil/tratamento farmacológico , Humanos , Masculino , Óxido Nítrico/metabolismo , Inibidores de Fosfodiesterase/farmacocinética , Piperazinas/efeitos adversos , Purinas , Sulfonas
3.
Indian J Exp Biol ; 1998 Dec; 36(12): 1273-5
Artigo em Inglês | IMSEAR | ID: sea-63016

RESUMO

Cataleptic effect of pentazocine in mice was affected by pretreatment with dexfenfluramine, fluoxetine, buspirone, p-chlorophenylalanine, cyproheptadine, mianserin, cisapride, ondansetron, pindolol and propranolol. The results suggest that drugs which influence the activity of central serotonergic systems do modulate pentazocine-induced catalepsy in mice.


Assuntos
Animais , Catalepsia/induzido quimicamente , Interações Medicamentosas , Masculino , Camundongos , Pentazocina/toxicidade , Serotonina/metabolismo , Serotoninérgicos/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA